Non -erosion gastroesophageal reflux disease
Conditions
Interventions
the Test group:Administer Xin Kai Ku Jiang Fa formula granules (9g of Pinellia ternata, 10g of Scutellaria baicalensis, 8g of Coptis chinensis, 3g of Fructus Evodiae, 10g of Radix Pseudostellariae, 10
At the same time, take orally pantoprazole enteric coated capsule simulant, once a time, once a day
Oral administration of flupenthizumab and melitracin tablets (Deanxit) as a simulated agent, taking 1 tablet in the morning and 1 tablet in the afternoon. The treatment period is 4 weeks.
the Control group:Give Pantoprazole enteric coated capsules (40mg × 7 pieces/box) orally, 1 piece/time, 1 time/day
Flupenthizumab Melitracen Tablets (Deanxit, 0.5mg: 10mg) × 20 tablets/box) orally, 1 tablet in the morning and 1 tablet in the afternoon
Simultaneously take a traditional Chinese medicine formula particle simulation agent (mainly composed of dextrin shaper, added to 1/10 of the treatment group's traditional Chinese medicine dose to ret
Sponsors
Beijing Xuanwu Traditional Chinese Medical Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. The clinical symptoms meet the diagnostic criteria of traditional Chinese medicine and Western medicine for NERD combined with mild to moderate anxiety and depression; 2. Between the ages of 18 and 65, regardless of gender; 3. No severe anxiety or depression, no suicidal tendencies; 4. The subject is informed and voluntarily signs an informed consent form.
Exclusion criteria
Exclusion criteria: Patients with gastric organic diseases such as erosive gastritis, gastric ulcer, and duodenal ulcer; Pregnant and lactating women; People with connective tissue diseases, diabetes and other endocrine and metabolic diseases, and menopausal syndrome; Individuals with severe primary heart, liver, lung, kidney, blood or serious diseases that affect their survival; Disabled patients (blind, deaf, mute, intellectually disabled, mentally disabled, physically disabled) as stipulated by law; Suspected or confirmed history of alcohol or drug abuse; According to the judgment of the researcher, other pathological changes that reduce the likelihood of enrollment or complicate enrollment, such as frequent changes in the work environment, may lead to loss of follow-up; Allergic constitution, such as a history of allergies to two or more drugs or foods; Or known to be allergic to the ingredients of this medicine; Patients participating in clinical trials of other drugs; Patients who are in a state of severe anxiety and depression and have a tendency to commit suicide.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main symptom score;Hamilton Anxiety Scale;Hamilton Depression Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| cholecystokinin;motilin;multi-channel impedance pH detection values;Electrogastrography ;substance P;5-hydroxytryptamine;dopamine;interleukin-6;interleukin-10;Calcitonin gene related peptide; | — |
Countries
china
Contacts
Public Contactlai yao liang
Beijing Xuanwu Traditional Chinese Medical Hospital
Outcome results
None listed